Generic Name and Formulations:
Diphenhydramine HCl 50mg; softgels; caps.
Indications for SLEEPINAL:
Short-term (≤ 2 weeks) treatment of insomnia.
50mg at bedtime.
Asthma. Lower respiratory disorders. Glaucoma. Hyperthyroidism. Hypertension. Cardiovascular disease. GI or urinary obstruction. Pregnancy. Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Concomitant diphenhydramine products (including topicals): not recommended. Additive effects with other other anticholinergics.
Drowsiness, dizziness, anticholinergic effects, paradoxical excitement.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage